The global xerostomia (dry mouth) therapeutics market is projected to exhibit considerable growth during the forecast period. The high prevalence of this problem, a rapid rise in the R&D activities related to the development of different drugs and treatment options by the major market players is a major factor anticipated to fuel the market during the forecast period. GlaxoSmithKline Plc, Church & Dwight Co., Inc., Colgate-Palmolive Co., Sun Pharmaceuticals Industries Ltd., Lupin Pharmaceuticals, Inc., Pfizer, Inc., Parnell Pharmaceuticals, Inc., Acacia Pharma Group Plc, Quest Products, LLC (OraCoat), EUSA Pharma NP, and so on are the key market players operating in the global xerostomia therapeutics market.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/xerostomia-dry-mouth-therapeutics-market
These market players are making hefty investments in their R&D sector to introduce new products and to perform innovation in their existing product offerings. For instance, in February 2020, Sunstar Americas Inc. had launched a wide range of Gum Hydral dry mouth relief products for the treatment of xerostomia or dry mouth. Gum Hydral is a kind of artificial saliva that provides advanced moisturizing and hydrating ingredients that perform their work like natural saliva to provide multisymptom relief in the dry mouth condition.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/xerostomia-dry-mouth-therapeutics-market
In November 2018, 3M Company had launched a new Xerostomia Relief Spray. 3M Xerostomia Relief Spray is a lipid-based spray that offers relief in the dry mouth by moisturizing and lubricating the mucosa. This spray can be used only after taking a prescription from a healthcare professional. The xerostomia relief spray is conveniently portable and ready to use without any premixing or preparation requirements by the affected person.
In October 2018, Synedgen had launched Moisyn Rinse for the treatment of the symptoms of xerostomia. Moisyn Rinse based on glycomic target-based therapy is being distributed by Prisyna, the oral care division of Synedgen. This rinse offers relief from the symptoms of dry mouth by moisturizing and lubricating of the oral cavity. Thus, the increasing product launches for the treatment of xerostomia are anticipated to be a major factor to drive the growth of the global xerostomia therapeutics market.
Global Xerostomia (Dry Mouth) Therapeutics Market Segmentation
By Product Type
- Artificial Saliva
- Dentifrices
- Salivary Stimulants
- Saliva Substitutes
- Drugs
- Salivary Pen
By Type
- Prescription
- OTC
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
